WallStreetZenWallStreetZen

NYSEMKT: CHRO
Chromocell Therapeutics Corp Stock Ownership - Who owns Chromocell Therapeutics?

Insider buying vs selling

Have Chromocell Therapeutics Corp insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Todd C. DavisDirector2024-02-2129,167$4.80
$140.00kBuy
Ezra M. FriedbergDirector2024-02-216,992$4.80
$33.56kBuy
Ezra M. FriedbergDirector2024-02-2113,649$4.80
$65.52kBuy
Ezra M. FriedbergDirector2024-02-2116,667$6.00
$100.00kBuy

1 of 1

CHRO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CHRO insiders and whales buy or sell their stock.

CHRO Shareholders

What type of owners hold Chromocell Therapeutics Corp stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Ezra M. Friedberg18.49%1,066,440$1.46MInsider
Motif Pharmaceuticals Ltd8.16%470,674$644.82kInsider
Boswell Prayer Ltd7.98%459,895$630.06kInsider
Aperture Healthcare Ventures Ltd7.40%426,566$584.40kInsider
Ame Equities LLC6.09%351,163$481.09kInsider
Anson Funds Management LP4.37%251,888$345.09kInstitution
Todd C. Davis0.51%29,167$39.96kInsider
Concourse Financial Group Securities Inc0.00%0$0.00Institution

1 of 1

CHRO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CHRO4.37%48.62%Net Buying
KA4.35%95.65%Net BuyingNet Buying
ALLR0.22%7.15%
ABVC1.20%98.80%
ADXN0.00%0.00%

Chromocell Therapeutics Stock Ownership FAQ

Who owns Chromocell Therapeutics?

Chromocell Therapeutics (NYSEMKT: CHRO) is owned by 4.37% institutional shareholders, 48.62% Chromocell Therapeutics insiders, and 47.01% retail investors. Ezra M. Friedberg is the largest individual Chromocell Therapeutics shareholder, owning 1.07M shares representing 18.49% of the company. Ezra M. Friedberg's Chromocell Therapeutics shares are currently valued at $1.46M.

If you're new to stock investing, here's how to buy Chromocell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.